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Despite numerous controlled trials, clinical practice
guidelines and cost-effective analyses, controversy per-
sists regarding the appropriate management strategy
for adult pharyngitis. In this perspective, we explore
this controversy by comparing two competing clinical
guidelines. Although the guidelines appear to make
widely diverging recommendations, we show that the
controversy centers on only a small proportion of
patients: those presenting with severe pharyngitis. We
examine recently published data to illustrate that this
seemingly simple problem of strep throat remains a
philosophical issue: should we give primacy to relieving
acute time-limited symptoms, or should we emphasize
the potential societal risk of antibiotic resistance? We
accept potentially over treating a minority of adult
pharyngitis patients with the most severe presentations
to reduce suffering in an approximately equal number
of patients who will have false negative test results if the
test-and-treat strategy were used.
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T
wenty-five years ago, I (RMC) first published a clinical
prediction model to derive the probability of streptococcal
pharyngitis in adult sore throat patients.
1 Over the years, most
authors have adopted this scoring system as the best validated
method for clinically evaluating adult pharyngitis. The model
was developed before the introduction of rapid antigen testing
to provide practicing physicians a method for making timely
clinical decisions given the delay in throat culture results.
Initially, the strategy we proposed of either empiric antibiotics
or testing before antibiotics administration for patients with
higher probability of streptococcal pharyngitis had no major
opposition. However, over the following years, we have gained a
better understanding about the epidemiology of acute adult
sore throat, recognizing the importance of group C beta-
hemolytic streptococcus.
2 In addition, the technology for rapid
antigen testing advanced. Consequently, thinking about adult
pharyngitis changed over the recent years, raising new con-
troversies that we address in this perspective.
Recent articles highlight competing management strategies
for adult pharyngitis patients.
3–10 Some articles, including
2001 American College of Physicians-American Society of
Internal Medicine (ACP-ASIM) “Principles of Appropriate Anti-
biotic Use for Acute Pharyngitis in Adults”
11–13 emphasize
patient symptom relief while the others, including 2002 release
of the Infectious Disease Society of America (IDSA) “Practice
Guidelines for the Diagnosis and Management of Group A
Streptococcal Pharyngitis,”
14 give higher priority to preventing
unnecessary antibiotic use. Table 1 outlines the similarities
and differences between those two guidelines for adult phar-
yngitis patients. Carefully considering this seemingly simple
and straightforward syndrome reveals an interesting philo-
sophical problem: should we give primacy to relieving acute
time-limited symptoms, or should we emphasize the potential
societal risk of antibiotic resistance?
Bisno and colleagues conclude in a 2002 viewpoint
4:
“... that the algorithm-based strategy proposed in the ACP-
ASIM guideline would result in the administration of
antimicrobial treatment to an unacceptably large number
of adults with nonstreptococcal pharyngitis.”
The IDSA’s primary concern with the algorithm-based
approach is the use of a pharyngitis prediction rule they feel
is not specific enough to differentiate group A Streptococcal
(GAS) from acute viral pharyngitis. They explicitly assume that
only group A beta-hemolytic streptococcal pharyngitis requires
antibiotic treatment. By endorsing a “test-and-treat” strategy
which favors testing all patients “suspected on clinical and
epidemiological grounds” and treating with antibiotics only
those with a positive result for group A beta-hemolytic strepto-
coccus, the IDSA expects to decrease “unnecessary” antibiotic
use, thereby, preventing further antibiotic resistance.
Although these contrasting approaches may seem far apart,
the controversy actually focuses on a fraction of adult pharyn-
gitis patients.
14–16 Even though the IDSA guidelines do not
endorse using the clinical pharyngitis score that we developed
in 1981 (Commonly known as the Centor score)
1 to distinguish
streptococcal from nonstreptococcal pharyngitis in high-risk
patients, they acknowledge its utility in identifying the subset of
patients at low risk for GAS. To use the Centor score, the
JGIM
We acknowledge that the designation severe pharyngitis is somewhat
arbitrary. We have used the designation previously.
15 Unpublished data
support that patients with scores of 3 and 4 have more severe difficulty
swallowing, which we equate with severity. Some patients with lower
scores will consider their symptoms severe.
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127examining clinician assigns 1 point each for: tonsillar exudates,
swollen tender anterior cervical nodes, fever history, and lack of
a cough, resulting in a score with a possible range of 0 to 4. The
ACP-ASIM and IDSA agree that patients with scores of 0 or 1
(mild pharyngitis) should be treated symptomatically with no
testing and no antibiotics because these patients have a very
low probability of streptococcal pharyngitis. Both agree that
patients having a score of 2 should undergo further testing. The
controversy, therefore, centers only on those patients with scores
of 3 or 4, herein referred to as severe pharyngitis. Figure 1 shows
the approximate severity distribution of adult patients presenting
with sore throat, only 30% of whom have severe symptoms.
1
As noted by Bisno and reported by Linder, 73% of adult
pharyngitis patients currently receive antibiotics.
4,17 In our
1981 pharyngitis study, almost half of the patients had mild
pharyngitis. If generalists simply followed the ACP-ASIM guide-
lines and neither tested nor provided antibiotics to these
patients, we would immediately decrease antibiotic use by
approximately one-third. Both guidelines agree with testing
the25%ofpatientswithscoresof2.Aslessthan20%ofpatients
with scores of 2 will test streptococcal positive, this strategy
would further decrease antibiotic use. By following the ACP-
ASIM guidelines as written (even with empiric antibiotics for all
severe pharyngitis), antibiotic usage would decrease from 73%
to 35%. Thus, the “unacceptably large number of adults”
receiving unnecessary antibiotics represent, at most, a small
proportion of the 30% of adult patients with severe pharyngitis.
The four commonly cited reasons for treating group A
beta-hemolytic streptococcal pharyngitis are prevention of non-
suppurative complications, prevention of suppurative compli-
cations, symptom resolution, and decreased transmission to
contacts. Below, we contrast the rationale for treating all
patients with severe pharyngitis with antibiotics with the two
main reasons proposed for the “test-and-treat” strategy: anti-
biotic anaphylaxis and generation of antibiotic resistance.
PREVENTING NON-SUPPURATIVE COMPLICATIONS
All strategies (immediate antibiotics, culture, or rapid testing)
will prevent most non-suppurative complications (acute rheu-
matic fever). Given the imperfect sensitivity of both culture and
rapid testing, these strategies may fail to prevent a low
percentage of acute rheumatic fever cases, but given the low
rate of this complication in the United States, acute rheumatic
fever risk should not influence our decision making. We have
no evidence that treatment prevents other non-suppurative
complications. We know of no evidence that the non-group A
streptococci cause non-suppurative complications.
PREVENTING SUPPURATIVE COMPLICATIONS
Preventing suppurative complications is more challenging.
18
One could argue that prompt antibiotics (either with empiric
therapy or rapid testing) will decrease the risk of peritonsillar
abscess compared to a 2-day delay in antibiotics experienced
from the culture strategy. A recent review of the microbiology of
peritonsillar abscess included group A and group C strepto-
cocci and anaerobic bacteria.
19 Most patients with positive
cultures (aspiration of the abscess) have negative throat
swabs.
20 Empiric antibiotics would likely prevent some sup-
purative complications above those prevented when treating
only rapid test positive patients.
Another potential reason for antibiotic therapy for severe
pharyngitis is to treat Fusobacterium necrophorum. Recent
data suggest that these bacteria may cause endemic acute
pharyngitis. F. necrophorum infections can cause Lemierre’s
Disease, peritonsillar abscess and persistent sore throat
symptoms.
21–24 While we do not yet know the probability of
progression to these complications, certainly empiric antibiotic
treatment would likely decrease their incidence. A recent
pediatric paper has documented the increasing incidence of
F. necrophorum infections (including Lemierre’s Syndrome)
over a recent 6-year period. The authors speculate that
Table 1. Comparison of adult pharyngitis guideline
recommendations for diagnostic testing and antibiotic treatment




0 Test No No
Treat No No
1 Test No No
Treat No No
2 Test Rapid antigen test
* Rapid antigen test





3 Test Rapid antigen test No test or Rapid antigen test






4 Test Rapid antigen test No Test
Treat PCN-V if rapid antigen
test is positive
Empiric PCN-V
*While the original IDSA (Infectious Disease Society of America) guide-
lines recommended throat cultures for negative rapid antigen tests, the
current revision no longer endorses routine throat cultures for adult
patients with a negative rapid antigen test. The ACP-ASIM guidelines
also do not recommend backup throat cultures for negative rapid
antigen tests.
Figure 1 Characteristics of 1,000 hypothetical patients with sore
throat.
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resurgence of this infection.
25
SYMPTOM RELIEF
Starting antibiotics on the day of clinical presentation will
decrease symptom duration. Zwart and colleagues showed that
immediate penicillin V, given for 7 days, decreased group A
streptococcal symptoms in 2.5 days, and non-group A strepto-
coccal symptoms, in 1 day in adult patients.
26 Previous
analyses suggested that antibiotics decrease symptom duration
by only 1 day. Zwart’s finding of greater benefit most likely
resides in the study population. His study focused on patients
at the heart of the controversy: those with pharyngitis scores of
3 or 4. No previous study of symptom benefit either restricted
enrollment to adults or just those patients having severe
pharyngitis.
As the Centor score increases, we suspect that symptom
severity also increases. Acute adult pharyngitis causes a
substantial several day quality of life decrement. Because
prompt antibiotics speed recovery from this discomfort, symp-
tom relief may dominate the treatment decision for many
patients with severe adult pharyngitis.
Most articles assume that only group A beta-hemolytic
streptococcal pharyngitis requires treatment. However, adult
patients clearly develop significant pharyngitis because of non-
group A beta-hemolytic streptococci, especially from groups C
and G.
2,27–29 Randomized trial data also suggest a symptom-
atic benefit for treating these patients.
26
PREVENTING TRANSMISSION
Immediate antibiotics decrease the communicability of bacte-
rial pharyngitis. Thus, immediate antibiotics convey an ad-
vantage to household contacts (important to many patients
with children). Because non-group A streptococci can cause
epidemic pharyngitis,
27 we assume that immediate treatment
will decrease communicability of those infections also.
ANTIBIOTIC ANAPHYLAXIS
Immediate treatment does give penicillin to more patients,
putting a few additional patients at risk for allergic reactions.
Penicillin allergic reactions did not have a significant influence




We cannot quantify the contribution that oral penicillin for
severe pharyngitis makes to the antibiotic resistance problem.
Despite over 50 years of penicillin use, we still do not have
penicillin resistant group A beta-hemolytic streptococci. Cer-
tainly, penicillin use could select out other bacteria for
resistance. As most other bacteria already have penicillin
resistance, we consider this risk less significant. Both guide-
lines argue for narrow spectrum antibiotics. Linder and
colleagues have shown in two articles that the use of broad-
spectrum antibiotics for pharyngitis is a major problem.
16,17
All experts agree that we should join in correcting these
inappropriate antibiotic prescriptions.
SUMMARY
Summarizing the strategy differences in Table 2, we present
percentage estimates from Zwart’s prospective study of adult
severe pharyngitis patients. In Zwart’s study, the prevalence of
group A streptococci is 50% and non-group A strep, 25%. The
“treat all severe pharyngitis patients” strategy provides antibi-
otic prescriptions to all adult patients having group A and non-
group A streptococcal pharyngitis. This strategy would likely
also prevent some cases of Lemierre’s Disease. The “test-and-
treat” strategy misses 10% of group A streptococcal pharyngi-
tis and all the non-group A pharyngitis. These cases are
missed because the rapid antigen test has a sensitivity of
approximately 90% for group A streptococci
30 and does not
test for either group C or group G streptococci. We favor
treating all severe pharyngitis to benefit this approximately
30% of severe pharyngitis patients that the testing strategy
would omit. Our analysis is certainly sensitive to both the
prevalence of group A and non-group A streptococci and the
sensitivity of the rapid antigen test utilized. Although Zwart’s
prevalence estimates are higher than previously reported in
the literature, we use these data from the only randomized
controlled trial that focused solely on patients with severe
pharyngitis.
Our strategy does result in prescribing antibiotics to 25%
of the severe pharyngitis patients having no streptococcal
infection. However, we believe that relieving suffering remains
the physician’s primary objective. Adult group A and non-
group A streptococcal pharyngitis causes severe, albeit limit-
ed, symptoms, which improve more rapidly with narrow
spectrum antibiotics. Using narrow spectrum antibiotics
(penicillin V or erythromycin for those who are penicillin
allergic) and limiting antibiotics to severe pharyngitis will
minimize new antibiotic resistance while affording ill patients
a faster recovery.
In summary, we believe the differences between the two
guidelines result from a difference in the perceived impor-
tance of antibiotic over versus under use.
10 We do not
believe that the ACP-ASIM algorithm-based guideline results
in an unacceptably large amount of unnecessary antibiotic
use. On the contrary, we accept over treating a minority of
Table 2. Treatment appropriateness for 300 hypothetical patients
































GAS Group A streptococcus, NGAS non-group A streptococcus, A
appropriate, I inappropriate.
129 Centor et al.: Pharyngitis Management: Defining the Controversy JGIMadult pharyngitis patients with the most severe presentations
in an effort to reduce suffering in an approximate equal
number of patients who will be under treated with the test
and treat strategy. The problem of antibiotic overuse for sore
throat is not a result of the algorithm-based approach
outlined in the ACP-ASIM guideline, but instead, reflect poor
adherence to the guideline as written.
16 Furthermore, we
believe strict adherence to the IDSA guideline will only
marginally reduce antibiotic overuse, and quite possibly,
increase undue suffering.
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